Open in Screener

SMWB

Similarweb Ltd

May 20 • 12:23PM ET

3.83

+0.14 3.94 %

Technology • Software - Application • Israel • Small • NYSE

Index	-	P/E	-	EPS (ttm)	-0.35	Insider Own	43.80%	Shs Outstand	87.60M	Perf Week	34.21%
Market Cap	332.63M	Forward P/E	12.96	EPS next Y	0.30	Insider Trans	0.25%	Shs Float	48.88M	Perf Month	41.67%
Enterprise Value	300.33M	PEG	0.13	EPS next Q	0.04	Inst Own	31.39%	Short Float	0.53%	Perf Quarter	48.83%
Income	-30.04M	P/S	1.15	EPS this Y	178.92%	Inst Trans	-9.21%	Short Ratio	0.38	Perf Half Y	-47.17%
Sales	289.39M	P/B	16.09	EPS next Y	76.33%	ROA	-12.14%	Short Interest	0.26M	Perf YTD	-48.93%
Book/sh	0.24	P/C	4.64	EPS next 5Y	97.04%	ROE	-134.06%	52W High	10.75 -64.42%	Perf Year	-48.31%
Cash/sh	0.82	P/FCF	35.01	EPS past 3/5Y	29.43% 24.47%	ROIC	-55.82%	52W Low	2.22 72.30%	Perf 3Y	-27.28%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	13.51% 24.76%	Gross Margin	78.99%	Volatility	14.00% 9.16%	Perf 5Y	-82.03%
Dividend TTM	-	EV/Sales	1.04	EPS Y/Y TTM	-60.98%	Oper. Margin	-3.84%	ATR (14)	0.27	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.66	Sales Y/Y TTM	12.16%	Profit Margin	-10.38%	RSI (14)	69.62	Recom	2.44
Dividend Gr. 3/5Y	- -	Current Ratio	0.66	EPS Q/Q	34.65%	SMA20	24.32%	Beta	1.13	Target Price	4.17
Payout	-	Debt/Eq	1.89	Sales Q/Q	10.12%	SMA50	36.22%	Rel Volume	1.80	Prev Close	3.68
Employees	1000	LT Debt/Eq	1.58	Earnings	May 13 BMO	SMA200	-38.22%	Avg Volume	684.20K	Price	3.83
IPO	May 12, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-39.39% 1.15%	Trades		Volume	579,559	Change	3.94%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-10-26	Downgrade	Citigroup	Buy → Neutral	$3
Feb-19-26	Downgrade	Needham	Buy → Hold
Feb-18-26	Downgrade	Northland Capital	Outperform → Market Perform	$5
Feb-18-26	Downgrade	Citizens	Mkt Outperform → Mkt Perform
Jan-13-26	Downgrade	Goldman	Buy → Neutral	$7.50
Dec-11-24	Initiated	Goldman	Buy	$16
Oct-21-24	Initiated	Needham	Buy	$11
Sep-10-24	Initiated	Northland Capital	Outperform	$15
Feb-15-24	Upgrade	Citigroup	Neutral → Buy	$6 → $10
Feb-07-24	Resumed	Jefferies	Buy	$10
Jan-12-23	Downgrade	Citigroup	Buy → Neutral	$10 → $7
May-24-22	Initiated	Cantor Fitzgerald	Overweight	$17
Feb-23-22	Upgrade	Barclays	Equal Weight → Overweight	$22
Jan-06-22	Upgrade	Jefferies	Hold → Buy	$20 → $22
Oct-21-21	Resumed	Barclays	Equal Weight	$22
Jun-07-21	Initiated	William Blair	Outperform
Jun-07-21	Initiated	Oppenheimer	Outperform	$27
Jun-07-21	Initiated	JP Morgan	Overweight	$31
Jun-07-21	Initiated	JMP Securities	Mkt Outperform	$29
Jun-07-21	Initiated	Jefferies	Hold	$23

Show Previous Ratings

May-13-26 07:01PM	Similarweb Ltd (SMWB) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic AI ... (GuruFocus.com) -8.65% +7.72%
04:53PM	Similarweb Ltd. Q1 2026 Earnings Call Summary (Moby)
07:13AM	Similarweb: Q1 Earnings Snapshot (Associated Press)
07:00AM	Similarweb Initiates CEO Succession Planning Process (Business Wire)
07:00AM	Similarweb Announces First Quarter 2026 Results (Business Wire)
07:00AM	Loading…
07:00AM	Similarweb and Manus Expand Data Coverage, Enabling Deeper Digital Marketing Insights and Smarter AI Agents (Business Wire)
Apr-30-26 08:00AM	Similarweb to Announce First Quarter 2026 Financial Results on May 13, 2026, Before Market Open (Business Wire)
Apr-10-26 09:37AM	Nike downgraded, IBM initiated: Wall Street's top analyst calls (The Fly) -6.05%
Mar-26-26 08:00AM	Similarweb Appoints Harel Beit-On as Chairman of its Board of Directors (Business Wire)
Mar-19-26 05:18PM	Similarweb report shows how GenAI is reshaping competitive dynamics (Quartz)
Mar-17-26 08:00AM	Similarweb Expands Ecommerce and Digital Shelf Analytics with Retail Intelligence Suite (Business Wire)
Mar-09-26 08:11PM	Why Does Similarweb (SMWB) Appear So Attractive (Insider Monkey)
Mar-04-26 08:55AM	NYSE Content Update: Alysa Liu Rings NYSE Bell After Winning Two Gold Medals (PR Newswire)
Mar-03-26 08:00AM	Similarweb Report Benchmarks AI Brand Visibility Winners and Overachievers (Business Wire)
07:30AM	Similarweb Files 2025 Annual Report on Form 20-F (Business Wire)
08:00AM	Loading…
Feb-26-26 08:00AM	HSBC Dismisses 'SaaSpocalypse' Fears Amid $1 Trillion Sell-Off, Says 'Software Is Already Eating AI' (Benzinga)
Feb-22-26 10:31AM	Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet (Benzinga)
Feb-20-26 12:21PM	Analyst Downgrades Hit Similarweb After Weak Sales and Outlook (Benzinga) +8.56%
Feb-18-26 05:43PM	Similarweb Q4 Earnings Call Highlights (MarketBeat) -34.62%
04:03PM	Similarweb Ltd (SMWB) Q4 2025 Earnings Call Highlights: Navigating Growth Amid AI Contract Delays (GuruFocus.com)
09:50AM	Palantir upgraded, Workday downgraded: Wall Street's top analyst calls (The Fly)
08:30AM	Similarweb Ltd. Q4 2025 Earnings Call Summary (Moby)
Feb-17-26 05:45PM	Similarweb (SMWB) Q4 Earnings Beat Estimates (Zacks)
04:52PM	Similarweb: Q4 Earnings Snapshot (Associated Press Finance)
04:15PM	Similarweb Announces Fourth Quarter and Fiscal 2025 Results (Business Wire)
Feb-10-26 08:00AM	Similarweb Launches AI Studio: Enterprise Intelligence That Puts Expert Market Research at Every Employee's Fingertips (Business Wire)
Feb-03-26 08:00AM	Similarweb and Bloomberg Expand Data Available on the Bloomberg Terminal (Business Wire) -10.17%
Feb-02-26 08:00AM	Similarweb to Announce Fourth Quarter 2025 Financial Results on February 17, 2026, After Market Close (Business Wire)
Jan-25-26 08:24PM	Goldman Sachs Turn Cautious on Similarweb Ltd. (SMWB) Amid Slowing Core Growth Metrics (Insider Monkey)
Jan-20-26 08:00AM	Similarwebs Digital 100 Awards Celebrate Web and App Growth in the US, UK, France, Germany, Japan, Australia, India, Brazil, and South Korea (Business Wire)
08:00AM	Loading…
08:00AM	Similarwebs Annual Digital 100 Report Finds Serious Utility Powers the Fastest Growing Websites and Apps (Business Wire)
Jan-13-26 08:00AM	Manus Collaborates with Similarweb to Give AI Agents Digital Marketing Insight (Business Wire) -7.77%
Jan-08-26 09:50AM	Alphabet Stock Gets an Upgrade. How Google's Gemini Will Beat ChatGPT. (Barrons.com)
07:46AM	Alphabet Stock Gets an Upgrade. How Google Will Beat ChatGPT. (Barrons.com)
Jan-06-26 06:08PM	Is OpenAI's ChatGPT losing ground to Google's Gemini? (CNBC TV)
Jan-02-26 12:14PM	Looking for the Big AI Winners of 2026? This Analyst Says Reddit Stock Should Top Your List. (Barchart) -5.07%
Dec-29-25 09:56AM	Wall Street Firms Bullish on Similarweb Ltd (SMWB) on Improving Industry Trends (Insider Monkey)
Dec-27-25 11:31AM	Google's Gemini Eating ChatGPT's Lunch: Market Share Gain From 5% To 18% Is 'Clearest Signal' That Alphabet Is Winning AI War (Benzinga)
Dec-19-25 12:22PM	OpenAI's Sora Soared. Then It Flatlined. (Barrons.com)
Dec-15-25 10:10AM	These Trump bets boomed. Now theyre huge busts (CNN Business)
Dec-08-25 11:08AM	Why Needham Backed Similarweb's AI Ambitions Despite Ongoing Profitability Struggles (Insider Monkey)
07:29AM	New data shows Gemini app momentum continues (Investing.com)
Dec-02-25 08:00AM	AI Discovery Surges: Similarweb's 2025 Generative AI Report Says (Business Wire)
05:28AM	OpenAIs Sam Altman declares code red after rivals make advances (Financial Times)
Nov-20-25 08:00AM	Similarweb Fall 2025 Updates Double Down on Data-Driven AI to Give Businesses a Competitive Edge (Business Wire) -6.63%
Nov-12-25 04:03PM	Similarweb Ltd (SMWB) Q3 2025 Earnings Call Highlights: Revenue Growth and Product Adoption ... (GuruFocus.com) -7.78%
02:31PM	Mark Zuckerberg's Patience 'Ran Out': Hyperbolic CTO Says Yann LeCun's Meta Exit Was Inevitable After $15 Billion Alexandr Wang Deal (Benzinga)
12:05PM	Why Similarweb Stock Is Plummeting Today (Motley Fool)
Nov-11-25 04:08PM	Similarweb: Q3 Earnings Snapshot (Associated Press Finance)
04:00PM	Similarweb Announces Third Quarter 2025 Results (Business Wire)
Nov-06-25 06:15PM	Yelp (YELP) Q3 Earnings and Revenues Top Estimates (Zacks)
Oct-27-25 07:30AM	Similarweb Names Ran Vered Chief Financial Officer (Business Wire)
Oct-20-25 09:00AM	Similarweb to Announce Third Quarter 2025 Financial Results on November 11, 2025, After Market Close (Business Wire)
Oct-15-25 08:00AM	Similarweb Web Intelligence 4.0: Data You Can Trust to Help You Win Your Market (Business Wire)
Oct-07-25 12:27PM	Anthropic plans to open India office, eyes tie-up with billionaire Ambani (TechCrunch)
Sep-29-25 04:56PM	DeepSeek: Everything you need to know about the AI chatbot app (TechCrunch)
05:30AM	Investors are betting big on prediction markets Kalshi and Polymarketwill the gamble pay off? (Fortune)
Sep-28-25 06:36PM	Threads Is on Track To Exceed X in Active Usage (Social Media Today)
Sep-15-25 12:14PM	X Claims Record High Download Numbers Last Week (Social Media Today)
08:00AM	Similarweb's 3rd Annual Global Ecommerce Report: Growth Shifts to Apps and AI (Business Wire)
Sep-09-25 08:00AM	Similarweb Launches MCP Server to Power AI Workflows with Comprehensive Digital Intelligence (Business Wire)
Sep-03-25 09:00AM	Morning Movers: United Therapeutics surges after TETON-2 met primary endpoint (TipRanks)
Sep-02-25 07:10AM	Similarweb Announces Planned CFO Departure After 10 Years Of Service (Business Wire) -6.54%
Aug-31-25 04:05PM	UK age check law seems to be hurting sites that comply, helping those that dont (TechCrunch)
Aug-29-25 11:46AM	ChatGPT: Everything you need to know about the AI-powered chatbot (TechCrunch)
Aug-28-25 04:10PM	Similarweb Names Tamar Rapaport-Dagim to its Board of Directors (Business Wire) +6.45%
Aug-27-25 03:27PM	Google and Grok are catching up to ChatGPT, says a16zs latest AI report (TechCrunch)
01:30AM	Spy Satellites, Road Cameras, Phone Trackers. How Alternative Data Companies Are Changing Investing. (Barrons.com)
Aug-21-25 01:35PM	Monday.com Stock Slides As SEO Traffic Declines Raise Growth Fears (Benzinga)
09:36AM	CoreWeave upgraded, Instacart downgraded: Wall Street's top analyst calls (The Fly)
Aug-18-25 10:46AM	Linktree goes dark in India and the company isnt sure why (TechCrunch)
Aug-14-25 10:00AM	Similarweb Wins Best Overall Marketing Analytics in MarTech Breakthrough Awards (Business Wire)
03:09AM	Similarweb Ltd (SMWB) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Expanding ... (GuruFocus.com)
Aug-12-25 04:54PM	Similarweb: Q2 Earnings Snapshot (Associated Press Finance) +18.73%
04:45PM	Similarweb Announces Second Quarter 2025 Results (Business Wire)
12:44PM	Threads now has more than 400 million monthly active users (TechCrunch)
09:28AM	Similarweb Ltd (SMWB) Q2 2025 Earnings Report Preview: What to Expect (GuruFocus.com)
Aug-11-25 09:28AM	Earnings To Watch: Similarweb Ltd (SMWB) Reports Q2 2025 Result (GuruFocus.com)
08:20AM	Perion Network (PERI) Q2 Earnings and Revenues Surpass Estimates (Zacks)
Aug-07-25 06:40PM	Yelp (YELP) Q2 Earnings and Revenues Surpass Estimates (Zacks) -5.29%
Aug-06-25 05:40PM	DHI Group (DHX) Q2 Earnings Surpass Estimates (Zacks)
Jul-31-25 11:41PM	Similarweb Launches GenAI Intelligence Toolkit to Track Brand Performance, Traffic on AI Platforms (Insider Monkey) -5.38%
Jul-30-25 11:50AM	Peloton Stock Jumps 17% as Analyst Predicts Price Hikes (Barrons.com)
Jul-28-25 05:10PM	Sanmina (SANM) Tops Q3 Earnings and Revenue Estimates (Zacks)
08:30AM	Similarweb to Announce Second Quarter 2025 Financial Results on August 12, 2025, After Market Close (Business Wire)
08:00AM	Similarweb Launches GenAI Intelligence Toolkit, Tracking Visibility and Traffic Across AI Chatbots (Business Wire)
Jul-25-25 04:11PM	AI referrals to top websites were up 357% year-over-year in June, reaching 1.13B (TechCrunch)
Jul-24-25 11:23AM	Amazon Gave Prime Day Shoppers More Time to Browse. Many Went to Walmart (Bloomberg)
Jul-17-25 12:43PM	Meta appoints generative AI VP to run Threads (TechCrunch)
Jul-10-25 07:31PM	Musk Vs Zuckerberg: Two Richest Men Battle Over Daily Social Media Users (Benzinga)
12:16PM	As X loses its CEO, daily usage is down and competition is growing (TechCrunch)
Jul-07-25 11:41AM	Threads is nearing Xs daily app users, new data shows (TechCrunch)
Jul-02-25 01:48PM	ChatGPT referrals to news sites are growing, but not enough to offset search declines (TechCrunch)
Jun-21-25 05:03AM	Europeans seek 'digital sovereignty' as US tech firms embrace Trump (Reuters)
Jun-10-25 05:30AM	News Sites Are Getting Crushed by Google's New AI Tools (The Wall Street Journal)
Jun-04-25 10:52AM	Bloomberg Expands Alternative Data Offering with Web Traffic Data from Similarweb (Business Wire)
May-28-25 08:00AM	Similarweb Launches AI Agents Powered by Comprehensive Digital Data, Delivering Results for Marketing and Sales Teams (Business Wire)
May-15-25 03:10AM	Similarweb Ltd (SMWB) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and New Product ... (GuruFocus.com)
May-13-25 05:25PM	Similarweb (SMWB) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -6.12%
04:22PM	Similarweb: Q1 Earnings Snapshot (Associated Press Finance)

SimilarWeb Ltd. engages in the provision of digital market intelligence platform. The firm develops measuring and monitoring tools of websites, and offers browser plugins and tools to explore the web and application programming interface. The company was founded by Or Offer, Nir Cohen, and Benjamin Seror in 2007 and is headquartered in Tel Aviv, Israel.

Co-FounderMr. Or Offer

Co-Founder & Chief Product OfficerMr. Benjamin Seror

Chief Technology OfficerMr. Ron Asher

Chief Business OfficerMr. Maoz Lakovski

Chief Revenue OfficerMs. Susan Dunn

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Offer Or	Chief Executive Officer	May 19 '26	Buy	3.58	53,000	189,650	4,694,396	May 20 09:09 AM
Offer Or	Chief Executive Officer	May 18 '26	Buy	3.20	3,105	9,936	4,641,396	May 20 09:09 AM
Rapaport-Dagim Tamar	Director	May 18 '26	Buy	3.22	40,000	128,880	63,584	May 19 11:00 AM
Campbell Lisa M	Director	Feb 19 '26	Proposed Sale	2.55	5,219	13,308		Feb 19 06:22 AM
Offer Or	Officer	Sep 08 '25	Proposed Sale	9.72	100,000	972,000		Sep 09 06:47 AM
Schwartz Jason Eric	Officer	Aug 14 '25	Proposed Sale	8.43	801,433	6,756,080		Aug 14 09:37 AM

Open in Screener

CNSP

Cns Pharmaceuticals Inc

May 20 • 12:20PM ET

4.67

-0.11 -2.30 %

Healthcare • Biotechnology • USA • Nano • NASD

CNSP Cns Pharmaceuticals Inc daily Stock Chart

Peers: LIXT SHPH IMNN TNXP BCDA

Index	-	P/E	-	EPS (ttm)	-29.63	Insider Own	0.00%	Shs Outstand	0.81M	Perf Week	-15.40%
Market Cap	6.83M	Forward P/E	-	EPS next Y	-1.66	Insider Trans	-	Shs Float	-	Perf Month	89.84%
Enterprise Value	4.11M	PEG	-	EPS next Q	-0.24	Inst Own	9.96%	Short Float	-	Perf Quarter	46.39%
Income	-16.49M	P/S	-	EPS this Y	95.38%	Inst Trans	5.84%	Short Ratio	0.03	Perf Half Y	-30.30%
Sales	0.00M	P/B	53.60	EPS next Y	-0.61%	ROA	-179.17%	Short Interest	0.04M	Perf YTD	-11.05%
Book/sh	0.09	P/C	2.31	EPS next 5Y	62.53%	ROE	-298.64%	52W High	16.56 -71.80%	Perf Year	-69.83%
Cash/sh	2.02	P/FCF	-	EPS past 3/5Y	95.26% 85.25%	ROIC	-23317.01%	52W Low	1.90 145.79%	Perf 3Y	-99.99%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	10.01% 15.31%	Perf 5Y	-100.00%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	99.30%	Oper. Margin	-	ATR (14)	0.82	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.88	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	51.56	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.88	EPS Q/Q	61.43%	SMA20	-1.70%	Beta	0.64	Target Price	10.00
Payout	-	Debt/Eq	3.29	Sales Q/Q	-	SMA50	38.59%	Rel Volume	0.03	Prev Close	4.78
Employees	8	LT Debt/Eq	0.00	Earnings	May 14 BMO	SMA200	-18.78%	Avg Volume	1.42M	Price	4.67
IPO	Nov 08, 2019	Option/Short	No / Yes	EPS/Sales Surpr.	-35.94% -	Trades		Volume	20,324	Change	-2.30%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-28-20	Downgrade	Ladenburg Thalmann	Buy → Neutral
Aug-24-20	Initiated	Ladenburg Thalmann	Buy	$11

May-14-26 08:00AM	CNS Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Strategic Transformation Progress (ACCESSWIRE) -9.24%
May-04-26 10:30AM	BC-Most Active Stocks (Associated Press) +239.23%
07:00AM	CNS Pharmaceuticals Announces Oversubscribed $22.5 Million Private Placement Financing (ACCESSWIRE)
Mar-11-26 08:35AM	CNS Pharmaceuticals Launches New Corporate Strategy Focused on Building a High-Value Neurology and Oncology Pipeline (ACCESSWIRE) -11.64%
Mar-02-26 08:25AM	CNS Pharmaceuticals Appoints Lynne Kelley, MD, FACS, as Chief Medical Officer, Completing Executive Leadership Team (ACCESSWIRE)
08:25AM	Loading…
Feb-17-26 08:25AM	CNS Pharmaceuticals Appoints Multiple Key Executives to Drive Company's Recently Initiated Strategic Transformation (ACCESSWIRE) -5.78%
Jan-27-26 09:00AM	CNS Pharmaceuticals Issues Letter to Shareholders (ACCESSWIRE)
Dec-17-25 07:00AM	CNS Pharmaceuticals Announces CEO Transition (ACCESSWIRE) -6.40%
Nov-17-25 08:35AM	CNS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update (ACCESSWIRE)
Nov-10-25 08:45AM	CNS Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentation at the Society of NueroOncology (SNO) 30th Annual Meeting (ACCESSWIRE)
Sep-13-25 09:05AM	CNS Pharmaceuticals upgraded to Buy at Maxim on TPI-287 roadmap (TipRanks)
Sep-03-25 09:15AM	CNS Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference (ACCESSWIRE)
Aug-15-25 08:05AM	CNS Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Corporate Update (ACCESSWIRE) -15.59%
Aug-14-25 09:15AM	CNS Pharmaceuticals to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech (ACCESSWIRE) -11.19%
Jul-22-25 08:45AM	CNS Pharmaceuticals to Participate in the Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference (ACCESSWIRE)
08:40AM	Loading…
08:40AM	JTC Team Virtual Investor "What's Your Story" Summer Spotlight On-Demand Conference Now Live (ACCESSWIRE)
Jul-18-25 08:00AM	CNS Pharmaceuticals Announces Reverse Stock Split (ACCESSWIRE) -10.71%
Jul-09-25 09:32AM	CNS Pharmaceuticals Participates in Virtual Investor CEO Connect Segment (ACCESSWIRE)
Jun-24-25 09:15AM	CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment Discussing Glioblastoma Multiforme (GBM) and Lead Product Candidate TPI 287 (ACCESSWIRE)
Jun-05-25 08:05AM	CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit (ACCESSWIRE)
May-16-25 08:05AM	CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate Update (ACCESSWIRE)
May-13-25 09:35AM	CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) +12.40%
07:00AM	CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287 (ACCESSWIRE)
Apr-02-25 08:46AM	CNS Pharmaceuticals reports FY24 EPS ($38.87) vs. ($12,509.11) last year (TipRanks)
Mar-25-25 08:00AM	CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme (ACCESSWIRE) -51.78%
Feb-26-25 09:05AM	CNS Pharmaceuticals Provides Update on Current Cash Position and NASDAQ Listing (ACCESSWIRE)
Feb-20-25 09:00AM	CNS Pharmaceuticals to Present at the 18th Annual European Life Sciences CEO Forum (ACCESSWIRE) -10.50%
Feb-19-25 09:00AM	CNS Pharmaceuticals, Inc. Participates in the Virtual Investor 'Top 5 for '25' On-Demand Conference (ACCESSWIRE) -41.19%
08:30AM	CNS Pharmaceuticals Announces Reverse Stock Split (ACCESSWIRE)
Feb-18-25 09:00AM	CNS Pharmaceuticals to Present at 6th Glioblastoma Drug Development Summit (ACCESSWIRE)
08:00AM	Loading…
Feb-10-25 08:00AM	CNS Pharmaceuticals to Present at the BIO CEO & Investor Conference (ACCESSWIRE) +10.46%
Dec-05-24 09:10AM	CNS Pharmaceuticals to Host Virtual Analyst and Investor Day on December 11, 2024 (ACCESSWIRE)
09:10AM	CNS Pharmaceuticals to Host Virtual Analyst & Investor Day on December 11, 2024 (ACCESS Newswire)
Nov-25-24 09:00AM	CNS Pharmaceuticals Presents Update from Ongoing Potentially Pivotal Study of Berubicin Compared with Lomustine in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy (ACCESSWIRE) -7.56%
Nov-18-24 08:55AM	CNS Pharmaceuticals Announces Abstract Accepted for Poster Presentation at the 29th Annual Meeting of the Society for Neuro-Oncology (SNO 2024) (ACCESSWIRE) +14.18%
Nov-15-24 09:10AM	CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results (ACCESSWIRE) -11.61%
Nov-04-24 09:15AM	CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment (ACCESSWIRE)
Nov-01-24 09:00AM	CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement (ACCESSWIRE)
Oct-23-24 02:50PM	CNS Pharmaceuticals Announces Pricing of $3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) -10.02%
Oct-10-24 09:00AM	CNS Pharmaceuticals Participates in Virtual Investor KOL Connect Segment (ACCESSWIRE)
Oct-08-24 09:15AM	CNS Pharmaceuticals to Participate in the 2024 Healthcare Virtual Summit Presented by Maxim Group LLC (ACCESSWIRE) +11.37%
Sep-23-24 09:00AM	CNS Pharmaceuticals to Present at the 24th Annual Biotech in Europe Forum (ACCESSWIRE)
Sep-12-24 09:00AM	CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement (ACCESSWIRE) -5.58%
Sep-04-24 09:05AM	CNS Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference (ACCESSWIRE)
Sep-03-24 08:00AM	IBN Announces Latest Episode of The BioMedWire Podcast featuring John Climaco, CEO of CNS Pharmaceuticals Inc. (GlobeNewswire)
Aug-27-24 09:10AM	CNS Pharmaceuticals to Participate in at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar (ACCESSWIRE) -7.11%
Aug-22-24 09:15AM	CNS Pharmaceuticals to Participate in Virtual Investor CEO Connect Segment (ACCESSWIRE)
Aug-15-24 08:00AM	CNS Pharmaceuticals Reports Second Quarter 2024 Financial Results (ACCESSWIRE)
Jul-30-24 07:00AM	CNS Pharmaceuticals Expands Pipeline with In-License of Late Stage, Novel Potential Blood Brain Barrier Permeable Abeotaxane for Treatment of Brain Malignancies (ACCESSWIRE) -60.58%
Jul-25-24 09:05AM	CNS Pharmaceuticals Announces Acceptance of Abstract for Poster Presentation at the 2024 SNO/ASCO CNS Cancer Conference (ACCESSWIRE)
Jul-16-24 09:15AM	CNS Pharmaceuticals to Participate in the Virtual Investor Closing Bell Series (ACCESSWIRE) -5.93%
Jul-11-24 07:29AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace) +20.00%
Jul-03-24 11:10AM	CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement (ACCESSWIRE) +15.87%
Jun-26-24 08:00AM	CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement (ACCESSWIRE) -35.21%
Jun-14-24 03:11PM	CNS Pharmaceuticals Announces Pricing of Registered Direct Offering and Concurrent Private Placement (ACCESSWIRE) -22.93%
Jun-10-24 08:00AM	JTC Team Announces Participating Company Line-Up for the Virtual Investor Pitch Conference on June 17-18, 2024 (ACCESSWIRE) -27.72%
Jun-03-24 08:05AM	CNS Pharmaceuticals Announces Reverse Stock Split (ACCESSWIRE) -39.87%
May-20-24 08:30AM	CNS Pharmaceuticals to Present at Alliance Global Partner's 2024 Healthcare Company Showcase (ACCESSWIRE)
May-16-24 11:53AM	CNSP Stock Earnings: CNS Pharmaceuticals Reported Results for Q1 2024 (InvestorPlace) +12.68%
07:45AM	CNS Pharmaceuticals Reports First Quarter 2024 Financial Results (ACCESSWIRE)
Apr-23-24 09:00AM	CNS Pharmaceuticals to Present at the LSX World Congress 2024 (ACCESSWIRE) +5.47%
Apr-22-24 10:15AM	CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break: The CNSP Opportunity (ACCESSWIRE)
Apr-01-24 11:52PM	CNSP Stock Earnings: CNS Pharmaceuticals Reported Results for Q4 2023 (InvestorPlace) -14.54%
05:00PM	CNS Pharmaceuticals Reports Full Year 2023 Financial Results and Highlights Recent Corporate and Clinical Achievements (ACCESSWIRE)
09:05AM	CNS Pharmaceuticals to Present at Two Investor Conferences in April (ACCESSWIRE)
Jan-29-24 09:00PM	CNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offering (ACCESSWIRE) -20.94% -27.67%
Jan-18-24 08:45AM	Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors (ACCESSWIRE)
Jan-17-24 08:45AM	CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) (ACCESSWIRE)
Dec-18-23 08:35AM	CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin (ACCESSWIRE) -23.12%
Dec-06-23 09:00AM	How CNS Pharmaceuticals Is Taking A Different Approach To Find A Treatment For Glioblastoma, A Cancer With A Poor Prognosis And No Cure (ACCESSWIRE)
Nov-22-23 09:05AM	CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy (ACCESSWIRE) +7.66%
Nov-16-23 10:00AM	CNS Pharmaceuticals To Release Interim Data By The End Of The Year For Potential Glioblastoma Drug Candidate (ACCESSWIRE) +9.38%
Nov-15-23 08:00AM	CNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year End (ACCESSWIRE) +14.97%
Oct-19-23 09:05AM	CNS Pharmaceuticals to Participate at the Virtual Investor Ask the CEO Conference (ACCESSWIRE) +11.24%
Oct-18-23 10:00AM	JTC Team Announces Presenting Company Line Up for the Virtual Investor Ask the CEO Conference Being Held October 24-25, 2023 (ACCESSWIRE) +11.25%
Oct-16-23 09:00AM	Glioblastoma Is the Most Aggressive Type of Brain Cancer, With No Cure - CNS Pharmaceuticals Innovative Approach To Treatment Could Offer Hope (ACCESSWIRE) +20.00%
Oct-11-23 08:45AM	CNS Pharmaceuticals' (NASDAQ:CNSP) Ongoing Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) Continues Rapid Pace of Enrollment with 229 Patients Enrolled to Date (ACCESSWIRE) +10.28%
Sep-07-23 08:45AM	CNS Pharmaceuticals (NASDAQ: CNSP) Reaches Milestone with Enrollment of 200 Patients in Ongoing Potentially Pivotal Study of Berubicin with the Treatment of Glioblastoma Multiforme (GBM) (ACCESSWIRE)
Sep-05-23 08:45AM	CNS Pharmaceuticals (NASDAQ: CNSP) to Present at the H.C. Wainwright 25th Annual Global Investment Conference (ACCESSWIRE) -6.51%
Aug-14-23 08:35AM	CNS Pharmaceuticals (NASDAQ: CNSP) Presents Updated Results from On-Going Potentially Pivotal Study of Berubicin in Adult Patients with Recurrent GBM (WHO Grade IV) After Failure of Standard First Line Therapy (ACCESSWIRE) -12.81%
07:35AM	CNS Pharmaceuticals Reports Second Quarter 2023 Financial Results and Reiterates Upcoming Milestones (ACCESSWIRE)
Aug-03-23 08:15AM	CNS Pharmaceuticals to Present at Benzinga's Virtual Biotech Conference (ACCESSWIRE)
08:00AM	CNS Pharmaceuticals Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM) (ACCESSWIRE)
Jul-27-23 09:05AM	CNS Pharmaceuticals (NASDAQ:CNSP) Announces Acceptance of Abstract for Poster Presentation at the 2023 SNO/ASCO CNS Cancer Conference (ACCESSWIRE)
Jul-05-23 08:45AM	CNS Pharmaceuticals to Participate in the Virtual Investor Summer Spotlight Series (ACCESSWIRE)
Jun-14-23 09:05AM	CNS Pharmaceuticals (NASDAQ:CNSP) to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest (ACCESSWIRE) +9.00%
May-25-23 09:05AM	CNS Pharmaceuticals (NASDAQ:CNSP) Achieves Over 50% Completion of Enrollment in Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme (GBM) (ACCESSWIRE)
May-15-23 08:35AM	CNS Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update (ACCESSWIRE)
May-08-23 08:45AM	Bettina M. Cockroft, M.D., M.B.A., Pharmaceutical and Biotech Industry Veteran, Joins CNS Pharmaceuticals Board of Directors (ACCESSWIRE) -5.99%
May-03-23 08:45AM	CNS Pharmaceuticals Investigating Potential Naked Short Selling; Retains Shareholder Intelligence Services, LLC (ACCESSWIRE) +26.32%
Apr-27-23 08:45AM	CNS Pharmaceuticals to Present at the Virtual Investor Spotlight Event - Rapidly Advancing GBM Pivotal Study (ACCESSWIRE)
Apr-17-23 06:54AM	Daily Vickers Top Buyers & Sellers for 04/17/2023 (Argus Research) +17.02%
Apr-10-23 08:45AM	Over 100 Patients Now Enrolled in CNS Pharmaceuticals (NASDAQ: CNSP) Potentially Pivotal Study Evaluating Berubicin for the Treatment of Glioblastoma Multiforme (GBM) (ACCESSWIRE)
Apr-06-23 09:05AM	CNS Pharmaceuticals Receives Approval from Competent Authority and Central Ethics Committee in Italy for Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM (ACCESSWIRE) -13.38%
Apr-03-23 08:05AM	CNS Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Corporate Update (ACCESSWIRE)
Mar-29-23 09:05AM	CNS Pharmaceuticals to Present at the Virtual Investor GBM Spotlight Event (PR Newswire)
Mar-13-23 07:05AM	CNS Pharmaceuticals Announces it Has No Exposure to Silicon Valley Bank Issues (PR Newswire) +6.40%
Mar-09-23 09:05AM	CNS Pharmaceuticals Continues Momentum in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM with First Patient Enrolled in Switzerland (PR Newswire) -8.16%
Feb-07-23 08:45AM	CNS Pharmaceuticals Announces First Patient Enrolled in Spain in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM (PR Newswire) -7.89%
Jan-12-23 08:45AM	CNS Pharmaceuticals Announces Investigator-Initiated Phase 1b/2 Trial to be Conducted at the Pomeranian Medical University in Poland (PR Newswire) -8.12%

CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. Its product pipeline includes berubicin, and CNS-12. The company was founded by Waldemar Priebe in July 2017 and is headquartered in Houston, TX.

CTPMr. Christopher S. Downs CPA

PresidentMr. Rami Levin M.B.A.

Chief Financial OfficerMr. Steve O'Loughlin M.B.A.

M.Sc.Mr. Eric Faulkner M.B.A.

Chief Business OfficerMr. Dylan Wenke M.B.A.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Charles Faith L.	Director	May 18 '26	Buy	4.79	7,100	34,002	7,100	May 20 09:03 AM

Open in Screener

OBIO

Orchestra BioMed Holdings Inc

May 20 • 12:23PM ET

3.97

-0.03 -0.63 %

Healthcare • Biotechnology • USA • Micro • NASD

OBIO Orchestra BioMed Holdings Inc daily Stock Chart

Peers: CAPR TNYA ATRC AORT BCDA

| Held by: VTI VXF SURI SCHA IWC SCHB AVSC IBBQ BIB

Index	-	P/E	-	EPS (ttm)	-1.13	Insider Own	31.16%	Shs Outstand	58.63M	Perf Week	-2.09%
Market Cap	238.02M	Forward P/E	-	EPS next Y	-1.39	Insider Trans	0.24%	Shs Float	41.22M	Perf Month	-6.03%
Enterprise Value	187.02M	PEG	-	EPS next Q	-0.40	Inst Own	41.04%	Short Float	2.36%	Perf Quarter	-0.13%
Income	-54.86M	P/S	7.27	EPS this Y	-43.89%	Inst Trans	4.04%	Short Ratio	4.34	Perf Half Y	-3.75%
Sales	32.72M	P/B	5.66	EPS next Y	12.68%	ROA	-68.42%	Short Interest	0.97M	Perf YTD	-4.22%
Book/sh	0.70	P/C	2.52	EPS next 5Y	4.89%	ROE	-161.12%	52W High	5.42 -26.71%	Perf Year	34.75%
Cash/sh	1.58	P/FCF	-	EPS past 3/5Y	20.91% -164.92%	ROIC	-65.19%	52W Low	2.20 80.68%	Perf 3Y	-73.78%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	111.62% -	Gross Margin	98.65%	Volatility	5.76% 5.45%	Perf 5Y	-60.84%
Dividend TTM	-	EV/Sales	5.72	EPS Y/Y TTM	36.35%	Oper. Margin	-167.96%	ATR (14)	0.23	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	7.01	Sales Y/Y TTM	1033.89%	Profit Margin	-167.63%	RSI (14)	46.65	Recom	1.38
Dividend Gr. 3/5Y	- -	Current Ratio	7.03	EPS Q/Q	32.86%	SMA20	-0.58%	Beta	0.51	Target Price	12.29
Payout	-	Debt/Eq	0.66	Sales Q/Q	-87.33%	SMA50	-6.30%	Rel Volume	0.36	Prev Close	4.00
Employees	86	LT Debt/Eq	0.64	Earnings	May 12 AMC	SMA200	3.67%	Avg Volume	224.14K	Price	3.97
IPO	Aug 04, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	23.34% -88.03%	Trades		Volume	38,324	Change	-0.63%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-10-25	Initiated	TD Cowen	Buy	$15
Aug-20-25	Downgrade	BTIG Research	Buy → Neutral
Mar-20-25	Initiated	BTIG Research	Buy	$12
Jan-02-25	Initiated	Barclays	Overweight	$16
Aug-22-24	Initiated	H.C. Wainwright	Buy	$14
Jul-25-24	Initiated	B. Riley Securities	Buy	$15
Jan-19-24	Initiated	Jefferies	Buy	$14
Feb-24-23	Initiated	Piper Sandler	Overweight	$15
Feb-07-23	Initiated	Chardan Capital Markets	Buy	$20

May-19-26 08:30AM	Orchestra BioMed to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-12-26 04:18PM	Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates (GlobeNewswire)
08:30AM	Orchestra BioMed Targeting BACKBEAT Trial Enrollment Completion By End of Q3 2026 and Data Presentation in Q2 2027 (GlobeNewswire)
May-06-26 08:01AM	Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement (GlobeNewswire)
08:00AM	Orchestra BioMed Receives $20 Million Payment from Medtronic Under Previously Announced Financing Agreement (GlobeNewswire)
09:00AM	Loading…
Apr-30-26 09:00AM	FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy (GlobeNewswire) +5.00%
Apr-23-26 12:00PM	Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026 (GlobeNewswire)
Mar-12-26 08:17AM	Orchestra BioMed Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update (GlobeNewswire)
Mar-03-26 08:00AM	Orchestra BioMed Announces Presentations Highlighting AVIM Therapy Potential Impact on Hypertensive Heart Disease and Heart Failure at THT and CRT (GlobeNewswire)
Feb-19-26 08:00AM	Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences (GlobeNewswire)
Feb-13-26 04:05PM	Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-12-26 09:00AM	Orchestra BioMed to Receive Up to $21 Million in Proceeds from Acquisition of Vivasure by Haemonetics (GlobeNewswire)
Dec-31-25 11:13AM	TD Cowen Initiates Orchestra BioMed (OBIO), Cites High-Margin Potential in Lead Cardiovascular Programs (Insider Monkey)
Dec-08-25 07:00AM	Orchestra BioMed Announces AVIM Therapy and Virtue SAB Program Presentations at ICI Meeting (GlobeNewswire)
Nov-29-25 01:25AM	Analyst Confidence in Orchestra BioMed Holdings (OBIO) High Amid Key Clinical and Strategic Advancements (Insider Monkey)
04:05PM	Loading…
Nov-26-25 04:05PM	Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-11-25 09:00AM	Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences (GlobeNewswire) +8.47%
07:31AM	What To Expect From Orchestra BioMed Holdings Inc (OBIO) Q3 2025 Earnings (GuruFocus.com)
Nov-10-25 05:30PM	Orchestra BioMed Holdings, Inc. (OBIO) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
04:10PM	Orchestra BioMed Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates (GlobeNewswire)
08:40AM	ADC Therapeutics SA (ADCT) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
Nov-04-25 10:00AM	Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks) -5.32%
Nov-03-25 08:00AM	Orchestra BioMed to Host Business Update Call on November 12, 2025 (GlobeNewswire)
Oct-28-25 08:00AM	Orchestra BioMed and Terumo Enter into New $30 Million Virtue SAB Strategic Agreements (GlobeNewswire)
Oct-27-25 09:00AM	Orchestra BioMed Announces First Patients Enrolled in Virtue SAB US Pivotal IDE Coronary Trial (GlobeNewswire)
Oct-09-25 08:00AM	Orchestra BioMed to Showcase Transformative Potential of AVIM Therapy in Keynote Presentation on Hypertensive Heart Disease at Georgia Innovation Summit (GlobeNewswire)
Sep-04-25 05:00PM	Orchestra BioMed Presents New AVIM Therapy Clinical Data at HRX Demonstrating Substantial and Sustained Blood Pressure Reductions that are Reproducible Upon Reactivation Following Washout (GlobeNewswire)
Aug-26-25 07:30AM	Orchestra BioMed Announces Publication of Clinical Data Demonstrating Favorable Blood Pressure and Hemodynamic Effects of AVIM Therapy in JACC: Clinical Electrophysiology (GlobeNewswire) +15.38%
Aug-14-25 08:00AM	Orchestra BioMed Announces Publication of AVIM Therapy Clinical Data in JACC: Advances Demonstrating Potential to Improve Cardiac Function in Patients with Hypertension and Diastolic Dysfunction (GlobeNewswire)
Aug-13-25 08:00AM	Campbellford Memorial Hospitals New Homecare Program Frees up 14.5 Hospital Bed-Days Per Patient Through a Partnership With Gotcare and OBIO® (Business Wire)
03:00PM	Loading…
Aug-12-25 03:00PM	Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Beats Revenue Estimates (Zacks) +7.94%
08:14AM	Orchestra BioMed Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates (GlobeNewswire)
Aug-08-25 07:00AM	Orchestra BioMed Announces Rollout of FDA-Approved BACKBEAT Global Pivotal Study Protocol Update Significantly Expanding Patient Eligibility (GlobeNewswire)
Aug-05-25 07:00AM	Orchestra BioMed Secures Over $111 Million in Proceeds and Committed Capital Following Completion of Strategic Transactions and Concurrent Public and Private Equity Offerings (GlobeNewswire)
Aug-04-25 05:55PM	CRISPR Therapeutics AG (CRSP) Reports Q2 Loss, Lags Revenue Estimates (Zacks) +9.84%
Aug-01-25 07:59AM	Orchestra BioMed Announces Pricing of $40 Million Public Offering (GlobeNewswire) -20.26%
Jul-31-25 04:02PM	Orchestra BioMed Announces Proposed Public Offering (GlobeNewswire)
04:01PM	Ligand and Medtronic Commit $70 Million in Strategic Capital to Orchestra BioMed (GlobeNewswire)
Jul-16-25 08:00AM	OBIO® Paves the Way for Companies to Succeed in Canada as a Stepping Stone to New Global Markets (Business Wire) +7.88%
Jun-18-25 09:30AM	Orchestra BioMed Showcases AVIM Therapy as Purpose-Built Solution for Hypertensive Heart Disease at CSI Frankfurt 2025 (GlobeNewswire) -11.01%
May-20-25 08:00AM	Sidoti Events, LLC's Virtual May Micro-Cap Conference (ACCESSWIRE)
May-12-25 05:40PM	Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +10.94%
04:28PM	Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones (GlobeNewswire)
May-07-25 08:30AM	Orchestra BioMed's AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure (GlobeNewswire)
May-06-25 05:10PM	Ultragenyx (RARE) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -5.47%
May-05-25 10:00AM	Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks) -6.57%
Apr-29-25 09:00AM	Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon (GlobeNewswire)
Apr-28-25 04:30PM	Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences (GlobeNewswire) -6.12%
Apr-23-25 09:00AM	Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting (GlobeNewswire)
Apr-22-25 07:00AM	Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy (GlobeNewswire)
Mar-31-25 07:05PM	Orchestra BioMed Holdings, Inc. (OBIO) Reports Q4 Loss, Lags Revenue Estimates (Zacks) -24.30%
04:21PM	Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update (GlobeNewswire)
Mar-24-25 09:10AM	Clene Inc. (CLNN) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
Feb-20-25 08:00AM	Orchestra BioMed to Present at Upcoming Investor Conferences (GlobeNewswire) -8.77%
Feb-18-25 08:00AM	Orchestra BioMed Appoints Vivek Reddy, M.D. as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of Bioelectronic Therapies Scientific Advisory Board (GlobeNewswire)
Feb-12-25 10:43AM	Orchestra BioMed Announces Data Demonstrating Favorable Impact of AVIM Therapy on Diastolic Dysfunction, a Key Driver of Heart Failure Progression, will be Presented as Late-Breaking Science at the THT 2025 Conference (GlobeNewswire)
Feb-05-25 08:00AM	Orchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of Directors (GlobeNewswire)
Dec-09-24 07:00AM	Orchestra BioMed Announces AVIM Therapy Program Presentations at ICI Meeting (GlobeNewswire) +9.54%
Nov-26-24 04:05PM	Orchestra BioMed to Participate in the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-12-24 06:05PM	Orchestra BioMed Holdings, Inc. (OBIO) Reports Q3 Loss, Tops Revenue Estimates (Zacks) -7.67% +7.24%
04:12PM	Orchestra BioMed Reports Third Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Nov-07-24 08:00AM	Orchestra BioMed to Participate in Jefferies London Healthcare Conference (GlobeNewswire) -5.50%
Aug-12-24 05:35PM	Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:20PM	Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Aug-08-24 09:35AM	Orchestra BioMed Holdings, Inc. (OBIO) Loses -25.35% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) +13.55%
Aug-01-24 10:01AM	Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Should You Buy? (Zacks) -7.18%
Jul-30-24 08:00AM	Orchestra BioMed Announces Appointment of Cardiovascular Device Industry Expert John Mack to Board of Directors (GlobeNewswire)
Jul-26-24 12:00PM	Orchestra BioMed Holdings, Inc. (OBIO) Upgraded to Buy: Here's What You Should Know (Zacks) -6.70%
09:55AM	Wall Street Analysts Believe Orchestra BioMed Holdings, Inc. (OBIO) Could Rally 102.61%: Here's is How to Trade (Zacks)
Jul-23-24 09:00AM	Precision Neuroscience Expands Executive Team as Brain Computer Interface Industry Rapidly Advances (GlobeNewswire)
Jun-24-24 08:07AM	Orchestra BioMed Holdings, Inc. (OBIO) Stock Jumps 7.3%: Will It Continue to Soar? (Zacks) +9.02%
Jun-04-24 08:00AM	Orchestra BioMed Announces Further Details on In-Person R&D Day in New York Featuring Key Opinion Leaders to Discuss AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024 (GlobeNewswire) +10.64%
Jun-03-24 12:00PM	All You Need to Know About Orchestra BioMed Holdings, Inc. (OBIO) Rating Upgrade to Buy (Zacks)
09:55AM	Does Orchestra BioMed Holdings, Inc. (OBIO) Have the Potential to Rally 135.64% as Wall Street Analysts Expect? (Zacks)
May-22-24 08:43AM	Orchestra BioMed to Participate in Jefferies Global Healthcare Conference (GlobeNewswire)
May-13-24 09:53PM	OBIO Stock Earnings: Orchestra BioMed Hldgs Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace) +13.04%
06:05PM	Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:58PM	Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
Apr-30-24 08:30AM	Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents (GlobeNewswire)
08:00AM	Orchestra BioMed to Host In-Person R&D Day in New York on AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024 (GlobeNewswire)
Mar-27-24 04:17PM	Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update (GlobeNewswire)
Mar-26-24 08:00AM	Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors (GlobeNewswire) +5.20%
Mar-13-24 08:00AM	Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting (GlobeNewswire)
Mar-07-24 08:00AM	Orchestra BioMed to Participate in Upcoming Investor Conferences (GlobeNewswire) -6.62%
Mar-06-24 08:37AM	Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients (GlobeNewswire)
Feb-26-24 08:00AM	Orchestra BioMed Presents New Data Showing Sustained Clinically Meaningful Reduction in 24-Hour Ambulatory Systolic Blood Pressure in Hypertensive Pacemaker Patients Treated with AVIM Therapy for Over 3 Years (GlobeNewswire)
Feb-16-24 09:13AM	Why Orchestra BioMed (OBIO) Might Surprise This Earnings Season (Zacks) -8.45%
Jan-08-24 07:30AM	Orchestra BioMed Announces Initiation of BACKBEAT Pivotal Study of AVIM Therapy in Hypertensive Pacemaker Patients (GlobeNewswire) +9.38%
Nov-13-23 04:21PM	Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +14.61% +13.08%
Nov-09-23 04:42PM	Orchestra BioMed to Present at Upcoming Investor Conferences (GlobeNewswire)
Oct-30-23 03:52PM	Billionaire Marc Lasrys Top 10 Stock Picks (Insider Monkey)
Sep-22-23 11:27AM	Lab Notes: Main Line firm spins off company that will focus on OTC product pipeline (American City Business Journals)
Sep-19-23 02:37PM	Rebel's Edge - September 19: $NIO, $BHC, $OBIO, and the Firing of MSU's Football Coach (TheStreet.com) +27.61%
07:30AM	Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT for the Treatment of Hypertension in Pacemaker Patients (GlobeNewswire)
Sep-06-23 05:00PM	Motus GI Appoints Medical Device Industry Veteran Scott Durbin to its Board of Directors (GlobeNewswire) -7.74%
Aug-10-23 04:34PM	Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +7.05%
Aug-08-23 08:30AM	Orchestra BioMed Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon in Patients with Coronary In-Stent Restenosis (GlobeNewswire)
Jul-27-23 09:47AM	Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) stock most popular amongst retail investors who own 36%, while hedge funds hold 28% (Simply Wall St.) -14.00%
Jun-28-23 02:16PM	Why Shares of Orchestra BioMed Holdings Jumped Wednesday (Motley Fool) +24.85%
Jun-26-23 08:00AM	Orchestra BioMed Set to Join Russell 3000® and other FTSE Russell Indexes (GlobeNewswire) -9.81%

Orchestra Biomed Holdings, Inc. engages in the provision of biomedical technologies to patients through risk-reward-sharing partnerships with medical device companies. The company was founded by David P. Hochman on May 25, 2020 and is headquartered in New Hope, PA.

FounderMr. David P. Hochman

FounderMr. Darren R. Sherman

Chief Financial OfficerMr. Andrew Lawrence Taylor M.B.A.

Executive Vice President of Corporate Development & StrategyMr. William Reed Little

Vice President of Human ResourcesMs. Lisa Daniels

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Aryeh Jason	Director	May 18 '26	Buy	3.75	665	2,494	118,118	May 20 08:00 AM
Aryeh Jason	Director	May 15 '26	Buy	3.90	8,971	34,987	117,453	May 19 08:00 AM
Hochman David P	See Remarks	May 15 '26	Buy	3.77	5,000	18,850	1,059,029	May 19 08:00 AM
Fain Eric S	Director	May 14 '26	Buy	4.13	20,000	82,600	91,709	May 18 08:00 AM
RTW INVESTMENTS, LP	10% Owner	Apr 27 '26	Sale	4.13	32	132	9,556,063	Apr 29 05:36 PM
Hochman David P	See Remarks	Mar 13 '26	Buy	4.29	10,000	42,900	1,086,467	Mar 16 04:54 PM
Hochman David P	See Remarks	Nov 14 '25	Buy	4.07	5,000	20,350	612,822	Nov 17 05:00 PM
Aryeh Jason	Director	Sep 19 '25	Buy	2.45	1,000	2,450	108,482	Sep 19 06:57 PM
Fain Eric S	Director	Aug 25 '25	Buy	2.61	5,760	15,034	71,709	Aug 25 07:04 PM
Sherman Darren	See Remarks	Aug 25 '25	Buy	2.62	3,000	7,860	926,837	Aug 25 07:04 PM
Hochman David P	See Remarks	Aug 21 '25	Buy	2.49	6,000	14,940	651,460	Aug 25 07:03 PM
Taylor Andrew Lawrence	Chief Financial Officer	Aug 25 '25	Buy	2.55	2,000	5,100	482,788	Aug 25 07:01 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Aug 01 '25	Buy	2.75	700,000	1,925,000	5,292,556	Aug 05 10:46 AM
Hochman David P	See Remarks	Aug 04 '25	Buy	2.75	20,000	55,000	349,331	Aug 04 06:16 PM
Fain Eric S	Director	Jun 26 '25	Sale	3.05	2,683	8,183	50,949	Jun 27 05:10 PM
Fain Eric S	Director	Jun 26 '25	Proposed Sale	3.05	2,683	8,194		Jun 26 03:11 PM

SMWB

Similarweb Ltd

CNSP

Cns Pharmaceuticals Inc

OBIO

Orchestra BioMed Holdings Inc

Upgrade your Finviz experience